William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sami Corwin has given his Buy rating due to a combination of factors including PTC Therapeutics’ promising pipeline and strategic preparations for upcoming product launches. The company is on track with regulatory discussions for Sephience, aimed at treating phenylketonuria, and anticipates FDA approval by mid-2025. This potential approval is bolstered by positive feedback from the European regulatory body, indicating a strong market entry.
Additionally, PTC Therapeutics has been proactive in building its commercial infrastructure, identifying key centers of excellence, and engaging with healthcare providers and insurers to ensure a successful launch. The company’s strategic pricing approach for Sephience, coupled with its robust clinical trial results for other pipeline products like PTC518 for Huntington’s disease, further supports the optimistic outlook. These factors collectively contribute to Corwin’s confidence in the company’s growth potential, justifying the Buy rating.
In another report released yesterday, RBC Capital also reiterated a Buy rating on the stock with a $58.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue